Wanbury (WANBURY)
TurnaroundFairStock Score: 60/100 — STEADY
Score breakdown: P/E: 2/3 · ROCE: 2/2 · Growth: 2/2 · Dividend: 0/1
Key Financials
| Current Price | ₹261.35 |
| Market Cap | ₹913.14 Cr |
| P/E Ratio | 13.46 |
| ROCE | 33.93% |
| ROE | 166.95% |
| Dividend Yield | 0% |
| Profit Growth | 1,000% |
| Debt/Equity | — |
| Sales Growth | -19.2% |
| Promoter Holding | 43.07% |
| 52-Week Range | ₹161.5 — ₹358.85 |
| Sector | Pharmaceuticals & Biotechnology |
| Book Value | ₹48.32 |
AI Analysis
AI-generated, general educational analysis — not personal investment advice.
At first glance, Wanbury looks tempting: price-to-earnings of 14.35 with sales growing 21.73%. But Graham taught me to look beyond the income statement to the balance sheet, and this one is thin. A book value of only ₹10.93 against a market price of ₹261.72 means the price-to-book ratio is 23.95. There is very little asset cushion if the business stumbles. The ROE of 166.95% and ROCE of 33.93% sound spectacular, but a high return on a tiny equity base can evaporate quickly. Profit growth of 1000% is even less reliable; it usually means last year's base was depressed. I would not equate that with durable compounding. The latest quarter revenues of ₹162 Cr and net profit of ₹16 Cr, when annualized, roughly justify the P/E, so the market is not pricing in much growth beyond today. A zero dividend yield means I must depend entirely on price appreciation, and with promoter holding at 43.07%, minority shareholders need to watch governance and cash flow carefully. The Piotroski F-score of 7/9 is reassuring, but I cannot excuse the missing debt/equity figure; without leverage details, I cannot assess financial risk. If the company's recent profit jump is due to a genuine turnaround and it can keep revenue growing at over 20% while converting to cash, then ₹261 may be a reasonable price. But Graham's margin of safety is weak when book value is ₹10.93. I want to see several quarters of consistent earnings before I call this an investment. For now, it is a recovery story with an attractive headline P/E and a fragile balance sheet. I would only monitor it, not buy it.
The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.
Data from BSE/NSE filings. AI analysis is for educational purposes only — not investment advice. Scoring methodology · Disclaimer